An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer
April 1, 2021 ― Biopharmaceutical and medical technology companies are true pillars of New Jersey’s economy and communities. With an overall economic impact of more than $83 billion (13% of New Jersey’s GDP) and more than 430,000 total life sciences-supported jobs in the state, they can be a catalyst for even greater economic growth — particularly for small business — which embraces far more entities than is usually understood by that term. Read the op-ed here.